Background
Methods
Statistical analysis
Radiotherapy
Results
Patients
Characteristic | SCLN status | SCLN status(after matching) | |||||
---|---|---|---|---|---|---|---|
Negative (n = 596) | Positive (n = 155) | P value | Negative (n = 140) | Positive (n = 140) | P value | ||
Age (years) | ≤65 years | 306(51.3%) | 99(63.9%) | 0.063 | 90(64.3%) | 85(60.7%) | 0.537 |
> 65 years | 290(48.7%) | 56(36.1%) | 50(35.7%) | 55(39.3%) | |||
Sex | Male | 432(72.5%) | 121(78.1%) | 0.348 | 104(74.3%) | 108(77.1%) | 0.577 |
Female | 164(27.5%) | 34(21.9%) | 36(25.7%) | 32(22.9%) | |||
Histology | SCC | 567(95.1%) | 143(92.3%) | 0.390 | 134(95.7%) | 130(92.9%) | 0.352 |
Others | 29(4.9%) | 12(7.7%) | 6(4.3%) | 10(7.1%) | |||
Tumor length | ≤5 cm | 207(34.7%) | 32(20.6%) | 0.027 | 30(21.4%) | 30(21.4%) | 1.000 |
> 5 cm | 389(65.3%) | 123(79.4%) | 110(78.6%) | 110(78.6%) | |||
Tumor diameter | ≤3 cm | 210(35.2%) | 34(21.9%) | 0.042 | 37(26.4%) | 30(21.4%) | 0.327 |
> 3 cm | 386(64.8%) | 121(78.1%) | 103(73.6%) | 110(78.6%) | |||
T stage | T1/T2 | 190(31.9%) | 29(18.7%) | 0.002 | 27(19.3%) | 27(19.3%) | 0.175 |
T3 | 174(29.2%) | 27(17.4%) | 39(27.9%) | 24(17.1%) | |||
T4 | 232(38.9%) | 99(63.9%) | 74(52.9%) | 89(63.6%) | |||
N stage | N0 | 158(26.5%) | 0(0%) | 0.000 | 17(12.1%) | 0(0.0%) | 0.180 |
N1 | 312(52.3%) | 33(21.3%) | 24(17.1%) | 33(23.6%) | |||
N2 | 111(18.6%) | 92(59.4%) | 84(60.0%) | 88(62.9%) | |||
N3 | 15(2.5%) | 30(19.4%) | 15(10.7%) | 19(13.6%) | |||
Chemotherapy | Yes | 384(64.4%) | 129(83.2%) | 0.002 | 32(22.9%) | 26(18.6%) | 0.376 |
No | 212(35.6%) | 26(16.8%) | 108(77.1%) | 114(81.4%) | |||
Tumor location | Cervical | 37(6.2%) | 9(5.8%) | 0.869 | 6(4.3%) | 9(6.4%) | 0.792 |
Upper | 121(20.3%) | 36(23.2%) | 35(25.0%) | 32(22.9%) | |||
Middle | 332(55.7%) | 88(56.8%) | 78(55.7%) | 80(57.1%) | |||
Lower | 106(17.8%) | 22(14.2%) | 21(15.0%) | 19(13.5%) | |||
number of LN | 0 | 160(26.8%) | 0(0.0%) | 0.000 | 17(12.1%) | 0(0.0%) | 0.137 |
1–2 | 310(52.0%) | 34(21.9%) | 24(17.1%) | 34(24.3%) | |||
> 3 | 126(21.1%) | 121(78.1%) | 99(70.7%) | 106(75.7%) |
Survival
Subgroup analysis of SCLN metastasis
Risk factors for survival
Variable | Harzard ratos for PFS | Harzard ratos for DMFS | ||
---|---|---|---|---|
P value | HR(95%CI) |
P
| HR(95%CI) | |
gender | 0.000 | 0.708(0.587–0.853) | 0.005 | 0.586(0.403–0.854) |
age | 0.972 | 1.003(0.856–1.175) | 0.001 | 0.595(0.436–0.813) |
Middle or lower with SCLN | 0.000 | 1.897(1.534–2.348) | 0.000 | 3.116(2.207–4.398) |
upper or cervical with SCLN | 0.841 | 1.036(0.736–1.457) | 0.709 | 0.874(0.430–1.777) |
diameter | 0.000 | 1.725(1.489–1.998) | 0.000 | 1.786(1.351–2.362) |
length | 0.000 | 1.631(1.406–1.891) | 0.000 | 1.797(1.355–2.383) |
CCR | 0.018 | 0.824(0.703–0.967) | 0.139 | 1.268(0.926–1.737) |
CCT | 0.283 | 0.912(0.770–1.079) | 0.055 | 1.345(0.993–1.822) |
Number of lymph node | 0.000 | 1.387(1.128–1.492) | 0.000 | 1.682(1.459–1.938) |
Variable | Harzard ratos for PFS | Harzard ratos for DMFS | ||
---|---|---|---|---|
P value | HR(95%CI) |
P
| HR(95%CI) | |
gender | 0.004 | 0.756(0.625–0.914) | 0.091 | 0.720(0.491–1.054) |
age | – | 0.015 | 0.676(0.493–0.927) | |
Middle and lower with SCLN | 0.025 | 1.303(1.033–1.644) | 0.002 | 1.819(1.242–2.664) |
diameter | 0.000 | 1.407(1.169–1.693) | 0.161 | 1.281(0.906–1.810) |
length | 0.496 | 1.068(0.884–1.290) | 0.931 | 1.016(0.713–1.447) |
CCR | 0.000 | 0.706(0.601–0.830) | – | |
Number of lymph node | 0.000 | 1.259(1.157–1.370) | 0.000 | 1.426(1.207–1.685) |